Impact of Herbal Preparations on Outcomes of Highly Active Antiretroviral Therapy: A One-Year Prospective Cohort Study.
10.1007/s11655-019-3156-x
- Author:
Qi-Jian SU
1
;
Ce SONG
1
;
Zhen-Zhen LU
1
;
Zhen-Wei LIU
1
;
Jian XIAO
2
;
Fa-Sheng WU
3
Author Information
1. Center for AIDS Research, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, 530011, China.
2. School of Basic Medical Science, Guangxi University of Chinese Medicine, Nanning, 530200, China.
3. Center for AIDS Research, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, 530011, China. wufasheng583@163.com.
- Publication Type:Journal Article
- Keywords:
Chinese medicine;
Qingdu Capsule;
Shenling Fuzheng Capsule;
aquired immune deficiency syndrome;
human immunodeficiency syndrome
- From:
Chinese journal of integrative medicine
2020;26(7):497-501
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate the impacts of two herbal preparations for human immunodeficiency virus/aquired immune deficiency syndrome (HIV/AIDS) patients, Shenling Fuzheng Capsule (, SLFZC) and Qingdu Capsule (, QDC), on the efficacy of highly active antiretroviral therapy (HAART).
METHODS:HIV/AIDS patients met the criteria were all enrolled in a 1-year cohort study, in which patients receiving HAART alone were designated as Group A, those receiving HAART in combination with SLFZC were designated as Group B, and those receiving HAART in combination with QDC were designated as Group C, 100 cases in each group. The dose of SLFZC was 1.48 g (4 capsules), 3 times daily, and QDC 1.56 g (4 capsules), 3 times daily. T cell subsets, HIV RNA and HIV-1 drug resistance were detected at enrollment and 1 year after treatment. Patients were followed up every 3 months, during which side-effects and other clinical data were recorded.
RESULTS:After 1-year treatment, the median increment in CD counts was 165.0, 178.0 and 145.0 cells/μL for Group A, B and C, respectively. HIV RNA was undetectable in 94% of patients in Group A, 96% in Group B and 92% in Group C. There were no differences regarding the increment in CD counts, HIV RNA and frequency of HIV-1 drug resistance mutations. Two of the 14 suspected side-effect symptoms, i.e. fatigue and dizziness, were lower in Groups B and C than in Group A (P<0.05, respectively) CONCLUSIONS: SLFZC and QDC do not have a negative impact on immunological and virological response to HAART; however, these preparations are not as potent in reducing HAART-associated side-effects as anticipated.
